|
|
|
|
We examined mortality among the 800 patients with early Parkinson's disease who were not requiring levodopa and who were randomly assigned in the DATATOP trial to receive deprenyl,tocopherol,combined treatments,or placebo.The mortality rate was unaffected by deprenyl,tocopherol,or combined treatment assignments and was about that expected for an age-and gender-matched US population without Parkinson's disease.Neither deprenyl, tocopherol,nor their combined treatments affected the duration of life in our early Parkinson's disease patients.The deprenyl-related delay in disability that we reported previously was not associated with a deprenyl- related reduction in mortality. |
|